CY2015043I1 - Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων - Google Patents

Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων

Info

Publication number: CY2015043I1
Authority: CY; Cyprus
Prior art keywords: compositions; compounds; protein kinase; kinase inhibitors; inhibitors
Prior art date: 2006-12-08

Application number

CY2015043C

Other languages

English (en)

Other versions

CY2015043I2 (el

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-08

Filing date

2015-11-02

Publication date

2016-04-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39370882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2015043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-11-02 Application filed by Novartis Ag filed Critical Novartis Ag

2016-04-13 Publication of CY2015043I1 publication Critical patent/CY2015043I1/el

2016-04-13 Publication of CY2015043I2 publication Critical patent/CY2015043I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)

CY2015043C 2006-12-08 2015-11-02 Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων CY2015043I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86929906P	2006-12-08	2006-12-08
US96644907P	2007-08-28	2007-08-28
PCT/US2007/085304 WO2008073687A2 (en)	2006-12-08	2007-11-20	Compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number	Publication Date
CY2015043I1 true CY2015043I1 (el)	2016-04-13
CY2015043I2 CY2015043I2 (el)	2016-04-13

Family

ID=39370882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY2015043C CY2015043I2 (el)	2006-12-08	2015-11-02	Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων

Country Status (30)

Country	Link
EP (1)	EP2091918B1 (el)
JP (3)	JP5208123B2 (el)
KR (1)	KR101149295B1 (el)
CN (2)	CN103641833A (el)
AU (3)	AU2007333394C1 (el)
BR (1)	BRPI0720264B1 (el)
CA (1)	CA2671744C (el)
CO (1)	CO6231028A2 (el)
CR (1)	CR10832A (el)
CY (1)	CY2015043I2 (el)
DK (1)	DK2091918T3 (el)
EA (1)	EA017405B9 (el)
EC (1)	ECSP099500A (el)
FR (1)	FR15C0058I2 (el)
GT (1)	GT200900147A (el)
HU (1)	HUS1500049I1 (el)
IL (1)	IL198936A0 (el)
LT (1)	LTC2091918I2 (el)
MA (1)	MA30923B1 (el)
ME (1)	ME00811B (el)
MX (1)	MX2009006081A (el)
NL (1)	NL300763I2 (el)
NO (3)	NO338069B1 (el)
PL (1)	PL2091918T3 (el)
PT (1)	PT2091918E (el)
SM (1)	SMP200900058B (el)
SV (1)	SV2009003290A (el)
TN (1)	TN2009000225A1 (el)
WO (1)	WO2008073687A2 (el)
ZA (1)	ZA200903601B (el)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100105729A1 (en) *	2006-10-06	2010-04-29	Kalypsys, Inc.	Aryl-substituted heterocyclic pde4 inhibitors as anti-inflammatory agents
TWI432427B (zh)	2006-10-23	2014-04-01	Cephalon Inc	作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
CN103641833A (zh) *	2006-12-08	2014-03-19	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
EP2099771A1 (en) *	2006-12-19	2009-09-16	Genentech, Inc.	Pyrimidine kinase inhibitors
AR065015A1 (es)	2007-01-26	2009-05-13	Smithkline Beecham Corp	Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
CN103588704B (zh)	2007-03-16	2016-09-14	斯克里普斯研究学院	粘着斑激酶抑制剂
TWI389893B (zh) *	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物
JP2010538004A (ja)	2007-08-28	2010-12-09	アイアールエム・リミテッド・ライアビリティ・カンパニー	キナーゼ阻害剤としての２−ビフェニルアミノ−４−アミノピリミジン誘導体
AU2008296479A1 (en) *	2007-08-28	2009-03-12	Dana Farber Cancer Institute	Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
SI2209778T1 (sl)	2007-09-21	2012-12-31	Array Biopharma, Inc.	Piridin-2-il-amino-I, 2,4-tiadiazol derivati kot aktivatorji glukokinaze za zdravljenje sladkorne bolezni
JP2011512413A (ja) *	2008-02-19	2011-04-21	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	Ｆａｋの阻害剤としてのアニリノピリジン
MX2010010968A (es) *	2008-04-07	2010-10-26	Irm Llc	Compuestos y composiciones como inhibidores de cinasa de proteina.
WO2009127642A2 (en) *	2008-04-15	2009-10-22	Cellzome Limited	Use of lrrk2 inhibitors for neurodegenerative diseases
EA029131B1 (ru)	2008-05-21	2018-02-28	Ариад Фармасьютикалз, Инк.	Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
BRPI0914927B8 (pt)	2008-06-17	2021-05-25	Astrazeneca Ab	composto, composição farmacêutica e uso de um composto
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
EP2331526A2 (en) *	2008-06-25	2011-06-15	Irm Llc	Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es) *	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
NZ603525A (en) *	2008-06-27	2015-02-27	Celgene Avilomics Res Inc	Pyrimidine based compound and uses thereof
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010025850A1 (de) *	2008-09-03	2010-03-11	Bayer Cropscience Ag	Heterozyklisch substituierte anilinopyrimidine als fungizide
US8343961B2 (en)	2009-03-31	2013-01-01	Arqule, Inc.	Substituted heterocyclic compounds
ES2659725T3 (es) *	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
SI2428508T1 (sl)	2009-05-08	2016-04-29	Astellas Pharma Inc.	Diamino heterociklična karboksamidna spojina
CN102459236B (zh) *	2009-05-27	2014-10-29	Abbvie公司	激酶活性的嘧啶抑制剂
KR101906146B1 (ko)	2009-08-17	2018-10-10	메모리얼 슬로안-케터링 캔서 센터	열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
MX339811B (es)	2009-09-16	2016-06-08	Celgene Avilomics Res Inc *	Conjugados e inhibidores de cinasa de proteina.
MA33926B1 (fr)	2009-12-17	2013-01-02	Merck Sharp & Dohme	Aminopyrimidines en tant qu'inhibiteurs de la syk
US8735417B2 (en)	2009-12-17	2014-05-27	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
RU2012132473A (ru)	2009-12-30	2014-02-10	Селджин Авиломикс,Инк	Лиганд-направленная ковалентная модификация белка
US20130005733A1 (en)	2010-03-09	2013-01-03	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
KR101531448B1 (ko)	2010-06-04	2015-06-24	에프. 호프만-라 로슈 아게	Lrrk2 조절제로서의 아미노피리미딘 유도체
PT2603081T (pt)	2010-08-10	2017-01-13	Celgene Avilomics Res Inc	Sal de besilato de um inibidor de btk
JP5956999B2 (ja)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ヘテロアリール化合物およびその使用
ES2776002T3 (es)	2010-11-01	2020-07-28	Celgene Car Llc	Compuestos heterocíclicos y usos de los mismos
CA3017869C (en)	2010-11-10	2021-07-27	Genentech, Inc.	Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2637502B1 (en)	2010-11-10	2018-01-10	Celgene CAR LLC	Mutant-selective egfr inhibitors and uses thereof
ES2643016T3 (es)	2010-12-17	2017-11-21	Novartis Ag	Formas cristalinas de 5-cloro-N2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-N4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
WO2012097479A1 (en) *	2011-01-21	2012-07-26	Abbott Laboratories	Bicyclic inhibitors of anaphastic lymphoma kinase
MX2013008791A (es) *	2011-02-02	2013-10-07	Irm Llc	Metodos para usar inhibidores de alk.
GB201104267D0 (en) *	2011-03-14	2011-04-27	Cancer Rec Tech Ltd	Pyrrolopyridineamino derivatives
AU2012250517B2 (en)	2011-05-04	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2012154520A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Pyridyl aminopyridines as syk inhibitors
WO2012154518A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines as syk inhibitors
RU2013154412A (ru)	2011-05-10	2015-06-20	Мерк Шарп И Доум Корп.	Аминопиримидины в качестве ингибиторов syc
US9364476B2 (en)	2011-10-28	2016-06-14	Celgene Avilomics Research, Inc.	Methods of treating a Bruton's Tyrosine Kinase disease or disorder
JP6353788B2 (ja)	2012-01-13	2018-07-04	エイシアバイオサイエンシーズインコーポレイテッド	抗がん剤としての複素環式化合物およびその使用
US9034885B2 (en)	2012-01-13	2015-05-19	Acea Biosciences Inc.	EGFR modulators and uses thereof
US9586965B2 (en)	2012-01-13	2017-03-07	Acea Biosciences Inc.	Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en)	2012-01-13	2016-10-11	Acea Biosciences Inc.	Heterocyclic compounds and uses thereof
CA2866852C (en)	2012-03-15	2020-12-29	Celgene Avilomics Research, Inc.	Solid forms of an epidermal growth factor receptor kinase inhibitor
MY185243A (en)	2012-03-15	2021-04-30	Celgene Car Llc	Salts of an epidermal growth factor receptor kinase inhibitor
FR2988722B1 (fr)	2012-04-03	2014-05-09	Sanofi Sa	Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
AU2013204563B2 (en)	2012-05-05	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
KR102156398B1 (ko)	2012-11-06	2020-09-15	상하이 포천 파마슈티컬 씨오 엘티디	Ａｌｋ 키나아제 억제제
US20150290204A1 (en)	2012-11-07	2015-10-15	Novartis Ag	Combination therapy
US9126950B2 (en)	2012-12-21	2015-09-08	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
WO2014124230A2 (en)	2013-02-08	2014-08-14	Celgene Avilomics Research, Inc.	Erk inhibitors and uses thereof
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
CN104109149B (zh) *	2013-04-22	2018-09-28	苏州泽璟生物制药有限公司	氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
CN105338980A (zh) *	2013-06-18	2016-02-17	诺华股份有限公司	药物组合
RU2656591C2 (ru) *	2013-07-11	2018-06-06	Бетта Фармасьютикалз Ко., Лтд	Модуляторы протеин-тирозинкиназы и способы их применения
DK3019496T3 (da)	2013-07-11	2019-12-09	Acea Therapeutics Inc	Pyrimidinderivater som kinaseinhibitorer
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
RU2016110874A (ru) *	2013-08-28	2017-10-04	Новартис Аг	Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
EP3757130A1 (en)	2013-09-26	2020-12-30	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
BR112016012506A8 (pt) *	2013-12-23	2018-01-30	Novartis Ag	combinações farmacêuticas, seus usos, e uso de um portador de dados
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR101656382B1 (ko) *	2014-02-28	2016-09-09	한국화학연구원	피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
KR20220126813A (ko)	2014-03-14	2022-09-16	노파르티스 아게	Lag-3에 대한 항체 분자 및 그의 용도
KR102461419B1 (ko)	2014-05-13	2022-11-02	메모리얼 슬로안 케터링 캔서 센터	Hsp70 조정물질 및 이의 제조 및 이용 방법
EA036922B1 (ru) *	2014-05-29	2021-01-15	Новартис Аг	Состав церитиниба
CN105272921A (zh) *	2014-06-09	2016-01-27	江苏奥赛康药业股份有限公司	一种制备Ceritinib的方法及其中间体化合物
CN103992262B (zh) *	2014-06-12	2015-11-11	苏州明锐医药科技有限公司	塞瑞替尼及其中间体的制备方法
KR101733733B1 (ko) *	2014-06-17	2017-05-11	한국화학연구원	피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
WO2016025561A1 (en)	2014-08-13	2016-02-18	Celgene Avilomics Research, Inc.	Forms and compositions of an erk inhibitor
MX2017003227A (es)	2014-09-13	2017-12-04	Novartis Ag	Terapias de combinacion de inhibidores de alk.
ES2796349T3 (es)	2014-09-29	2020-11-26	Hainan Xuanzhu Pharma Co Ltd	Inhibidor de la quinasa de linfoma anaplásico policíclico
ES2774448T3 (es)	2014-10-03	2020-07-21	Novartis Ag	Terapias de combinación
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es)	2014-10-14	2017-11-07	Dana Farber Cancer Inst Inc	Moléculas de anticuerpo que se unen a pd-l1
US20170252335A1 (en)	2014-10-17	2017-09-07	Novartis Ag	Combination of Ceritinib with an EGFR Inhibitor
WO2016098070A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016100882A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Combination therapies
WO2016098042A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
CN105777616B (zh) *	2014-12-26	2018-12-07	上海医药工业研究院	色瑞替尼的合成中间体及其制备方法
CN105777617B (zh) *	2014-12-26	2018-11-06	上海医药工业研究院	色瑞替尼的合成中间体及其制备方法
US9296721B1 (en) *	2015-02-13	2016-03-29	Yong Xu	Method for preparing ALK inhibitor ceritinib
EP3778604A1 (en)	2015-02-13	2021-02-17	Dana Farber Cancer Institute, Inc.	Lrrk2 inhibitors and methods of making and using the same
CA2976981A1 (en)	2015-03-04	2016-09-09	Novartis Ag	Chemical process for preparing pyrimidine derivatives and intermediates thereof
CN107530415A (zh)	2015-03-10	2018-01-02	艾杜罗生物科技公司	用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
CN106146387A (zh) *	2015-03-30	2016-11-23	湖北生物医药产业技术研究院有限公司	Alk抑制剂的制备方法
WO2016167511A2 (ko) *	2015-04-14	2016-10-20	한국화학연구원	N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101772134B1 (ko)	2015-04-14	2017-08-29	한국화학연구원	N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP3328848A1 (en)	2015-07-28	2018-06-06	Zentiva, K.S.	Solid forms of ceritinib free base
PT3317301T (pt)	2015-07-29	2021-07-09	Novartis Ag	Terapias de associação compreendendo moléculas de anticorpo contra lag-3
CN114272371A (zh)	2015-07-29	2022-04-05	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
CZ2015613A3 (cs)	2015-09-09	2017-03-22	Zentiva, K.S.	Způsob přípravy Ceritinibu
EP4219482A1 (en) *	2015-09-25	2023-08-02	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Compounds and methods for inhibiting jak
CN107949388B (zh)	2015-10-09	2021-10-26	艾森医药公司	吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
CN106565593B (zh) *	2015-10-10	2019-03-01	常州市勇毅生物药业有限公司	一种色瑞替尼中间体的制备方法
KR20180069071A (ko)	2015-11-03	2018-06-22	얀센 바이오테크 인코포레이티드	Pd-1 및 tim-3과 특이적으로 결합하는 항체 및 그의 용도
CN106699743B (zh) *	2015-11-05	2020-06-12	湖北生物医药产业技术研究院有限公司	嘧啶类衍生物及其用途
JP6634157B2 (ja)	2015-11-26	2020-01-22	ノバルティスアーゲー	ジアミノピリジン誘導体
CN106883213B (zh) *	2015-12-15	2021-04-20	合肥中科普瑞昇生物医药科技有限公司	一种egfr和alk激酶的双重抑制剂
CA3007671A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
WO2017153932A1 (en)	2016-03-10	2017-09-14	Novartis Ag	Strn-alk fusion as a therapeutic target in gastric cancer
WO2017175111A1 (en)	2016-04-04	2017-10-12	Novartis Ag	Strn-alk fusion as a therapeutic target in colorectal cancer
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
KR101937529B1 (ko) *	2016-07-26	2019-01-14	한국화학연구원	신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US10647713B2 (en) *	2016-10-21	2020-05-12	Nimbus Lakshmi, Inc.	TYK2 inhibitors and uses thereof
JP7503380B2 (ja)	2017-01-10	2024-06-20	ノバルティスアーゲー	Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬
US20200069685A1 (en)	2017-02-27	2020-03-05	Novartis Ag	Dosing schedule for a combination of Ceritinib and an anti-PD-1 antibody molecule
EP3606925A1 (en)	2017-04-07	2020-02-12	ACEA Therapeutics, Inc.	Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
US11179412B2 (en)	2017-12-04	2021-11-23	University of Pittsburgh—of the Commonwealth System of Higher Education	Methods of treating conditions involving elevated inflammatory response
CN110092759A (zh) *	2018-01-31	2019-08-06	陆柯潮	作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物
TW202015726A (zh)	2018-05-30	2020-05-01	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
KR20210025061A (ko) *	2018-06-29	2021-03-08	다나-파버 캔서 인스티튜트 인크.	세레블론(crbn)에 대한 리간드
CN109593065A (zh) *	2018-12-03	2019-04-09	重庆医科大学	一类hdac/alk双靶点抑制剂及其制备方法与应用
CN113395968B (zh) *	2019-06-25	2024-03-01	苏州亚盛药业有限公司	用于治疗疾病的fak抑制剂和btk抑制剂的组合
CN114302878A (zh)	2019-07-03	2022-04-08	大日本住友制药肿瘤公司	酪氨酸激酶非受体1(tnk1)抑制剂及其用途
EP4031578A1 (en)	2019-09-18	2022-07-27	Novartis AG	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN112538072B (zh) *	2019-09-21	2024-02-06	齐鲁制药有限公司	氨基嘧啶类egfr抑制剂
GB201915618D0 (en)	2019-10-28	2019-12-11	Univ Oslo	ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
AU2020385527B2 (en) *	2019-11-21	2023-04-13	Tyk Medicines, Inc.	Compound used as EGFR kinase inhibitor and use thereof
WO2021111311A2 (ko) *	2019-12-03	2021-06-10	삼진제약주식회사	국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체
KR102572704B1 (ko) *	2019-12-16	2023-08-30	한국화학연구원	신규한 피리미딘 유도체 및 이의 용도
WO2021190417A1 (zh) *	2020-03-23	2021-09-30	齐鲁制药有限公司	新型氨基嘧啶类egfr抑制剂
CN111484484B (zh) *	2020-04-13	2021-11-23	沈阳药科大学	含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
JP2023522863A (ja) *	2020-04-14	2023-06-01	斉魯制薬有限公司	Ｅｇｆｒ阻害剤としての三環式化合物
WO2023106881A1 (ko) *	2021-12-09	2023-06-15	주식회사 온코빅스	암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물
EP4450493A1 (en) *	2021-12-13	2024-10-23	Signet Therapeutics Inc.	Pyrimidine or pyridine derivative and medicinal use thereof
CN115368366A (zh) *	2022-08-02	2022-11-22	江苏省中医药研究院	嘧啶并吡唑类化合物及其应用
CN115448906B (zh) *	2022-09-26	2024-04-02	深圳大学	一种2-苯胺基嘧啶类衍生物及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0874846B1 (en) *	1995-11-01	2003-04-02	Novartis AG	Purine derivatives and processes for their preparation
ATE342892T1 (de) *	1998-08-29	2006-11-15	Astrazeneca Ab	Pyrimidine verbindungen
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9918035D0 (en) *	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
HUP0301117A3 (en) *	2000-02-17	2004-01-28	Amgen Inc Thousand Oaks	Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
FR2818642B1 (fr) *	2000-12-26	2005-07-15	Hoechst Marion Roussel Inc	Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
JP4320705B2 (ja) *	2001-03-23	2009-08-26	バイエルコーポレイション	Ｒｈｏキナーゼ阻害剤
MXPA03008658A (es) *	2001-03-23	2005-04-11	Bayer Ag	Inhibidores de rho-cinasa.
ES2305435T3 (es) *	2002-01-10	2008-11-01	Bayer Healthcare Ag	Inhibidores de la rho-quinasa.
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
GB0319227D0 (en) *	2003-08-15	2003-09-17	Novartis Ag	Organic compounds
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
CN1798734A (zh) *	2003-04-04	2006-07-05	Irm责任有限公司	作为蛋白激酶抑制剂的新化合物和组合物
US20050014753A1 (en) *	2003-04-04	2005-01-20	Irm Llc	Novel compounds and compositions as protein kinase inhibitors
MXPA06001758A (es) *	2003-08-15	2006-08-11	Irm Llc	Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
BRPI0413616B8 (pt) *	2003-08-15	2021-05-25	Irm Llc	2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
GB0407723D0 (en) *	2004-04-05	2004-05-12	Novartis Ag	Organic compounds
EP1598343A1 (de) *	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
US8211929B2 (en) *	2004-12-30	2012-07-03	Exelixis, Inc.	Pyrimidine derivatives as kinase modulators and method of use
TWI432427B (zh) *	2006-10-23	2014-04-01	Cephalon Inc	作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
CN103641833A (zh) *	2006-12-08	2014-03-19	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物

2007
- 2007-11-20 CN CN201310574409.XA patent/CN103641833A/zh active Pending
- 2007-11-20 AU AU2007333394A patent/AU2007333394C1/en active Active
- 2007-11-20 BR BRPI0720264-4A patent/BRPI0720264B1/pt active IP Right Grant
- 2007-11-20 EA EA200970557A patent/EA017405B9/ru not_active IP Right Cessation
- 2007-11-20 DK DK07864693.2T patent/DK2091918T3/en active
- 2007-11-20 PT PT78646932T patent/PT2091918E/pt unknown
- 2007-11-20 JP JP2009540379A patent/JP5208123B2/ja active Active
- 2007-11-20 WO PCT/US2007/085304 patent/WO2008073687A2/en active Application Filing
- 2007-11-20 ME MEP-2009-216A patent/ME00811B/me unknown
- 2007-11-20 PL PL07864693T patent/PL2091918T3/pl unknown
- 2007-11-20 MX MX2009006081A patent/MX2009006081A/es active IP Right Grant
- 2007-11-20 EP EP07864693.2A patent/EP2091918B1/en active Active
- 2007-11-20 KR KR1020097014175A patent/KR101149295B1/ko active Protection Beyond IP Right Term
- 2007-11-20 CA CA2671744A patent/CA2671744C/en active Active
- 2007-11-20 CN CN201310573341.3A patent/CN103641816A/zh active Pending
2009
- 2009-05-25 IL IL198936A patent/IL198936A0/en active Protection Beyond IP Right Term
- 2009-05-25 ZA ZA2009/03601A patent/ZA200903601B/en unknown
- 2009-05-27 MA MA31924A patent/MA30923B1/fr unknown
- 2009-05-28 CR CR10832A patent/CR10832A/es unknown
- 2009-06-03 GT GT200900147A patent/GT200900147A/es unknown
- 2009-06-03 TN TNP2009000225A patent/TN2009000225A1/fr unknown
- 2009-06-08 SV SV2009003290A patent/SV2009003290A/es unknown
- 2009-06-30 NO NO20092472A patent/NO338069B1/no active Protection Beyond IP Right Term
- 2009-07-02 SM SM200900058T patent/SMP200900058B/it unknown
- 2009-07-08 EC EC2009009500A patent/ECSP099500A/es unknown
- 2009-07-08 CO CO09070739A patent/CO6231028A2/es active IP Right Grant
2010
- 2010-08-09 AU AU2010210019A patent/AU2010210019C1/en not_active Ceased
- 2010-08-09 AU AU2010210018A patent/AU2010210018B2/en not_active Ceased
2012
- 2012-07-06 JP JP2012152703A patent/JP5513558B2/ja active Active
2013
- 2013-02-19 JP JP2013030284A patent/JP2013144683A/ja active Pending
2015
- 2015-08-26 FR FR15C0058C patent/FR15C0058I2/fr active Active
- 2015-09-29 LT LTPA2015034C patent/LTC2091918I2/lt unknown
- 2015-10-02 HU HUS1500049C patent/HUS1500049I1/hu unknown
- 2015-10-07 NL NL300763C patent/NL300763I2/nl unknown
- 2015-11-02 CY CY2015043C patent/CY2015043I2/el unknown
2016
- 2016-02-29 NO NO20160333A patent/NO20160333A1/no not_active Application Discontinuation
- 2016-08-10 NO NO2016014C patent/NO2016014I2/no unknown

Also Published As

Publication number	Publication date
AU2010210019C1 (en)	2013-02-14
SV2009003290A (es)	2010-08-17
KR101149295B1 (ko)	2012-07-05
CR10832A (es)	2009-07-14
ECSP099500A (es)	2009-08-28
PT2091918E (pt)	2014-11-24
SMP200900058B (it)	2010-11-12
JP2012229240A (ja)	2012-11-22
EP2091918B1 (en)	2014-08-27
LTC2091918I2 (lt)	2017-04-10
PL2091918T3 (pl)	2015-02-27
AU2010210018B2 (en)	2012-02-02
SMAP200900058A (it)	2010-01-19
CN103641816A (zh)	2014-03-19
FR15C0058I1 (el)	2015-10-02
AU2007333394B2 (en)	2011-02-03
NO20160333A1 (no)	2016-02-29
CO6231028A2 (es)	2010-12-20
KR20090087127A (ko)	2009-08-14
EA017405B9 (ru)	2014-05-30
DK2091918T3 (en)	2014-12-01
IL198936A0 (en)	2010-02-17
CA2671744C (en)	2012-08-28
EP2091918A2 (en)	2009-08-26
WO2008073687A2 (en)	2008-06-19
HUS1500049I1 (hu)	2017-10-30
EA017405B1 (ru)	2012-12-28
NO338069B1 (no)	2016-07-25
JP5208123B2 (ja)	2013-06-12
MA30923B1 (fr)	2009-11-02
JP5513558B2 (ja)	2014-06-04
NO20092472L (no)	2009-09-02
ME00811B (me)	2012-03-20
JP2013144683A (ja)	2013-07-25
AU2010210019A1 (en)	2010-09-02
FR15C0058I2 (fr)	2016-03-11
GT200900147A (es)	2010-01-27
NL300763I1 (el)	2016-02-09
MX2009006081A (es)	2009-06-17
WO2008073687A3 (en)	2008-07-31
CN103641833A (zh)	2014-03-19
NO2016014I2 (no)	2016-08-10
AU2010210018A1 (en)	2010-09-02
NO2016014I1 (el)	2016-08-10
TN2009000225A1 (en)	2010-10-18
AU2010210019B2 (en)	2012-08-02
ZA200903601B (en)	2011-01-26
AU2007333394A1 (en)	2008-06-19
CA2671744A1 (en)	2008-06-19
BRPI0720264A2 (pt)	2011-05-10
JP2010512329A (ja)	2010-04-22
BRPI0720264B1 (pt)	2022-03-03
NL300763I2 (el)	2016-02-09
EA200970557A1 (ru)	2009-12-30
CY2015043I2 (el)	2016-04-13
AU2007333394C1 (en)	2011-08-18

Publication	Publication Date	Title
CY2015043I2 (el)	2016-04-13	Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
CY2019013I1 (el)	2019-11-27	Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CR10755A (es)	2009-06-04	Compounds and compositions as protein kinase inhibitors
BRPI0719797A2 (pt)	2017-10-24	compostos e composições como inibidores de proteína cinase
HRP20141260T1 (en)	2015-03-13	Compounds and compositions as protein kinase inhibitors
DE602007008837D1 (de)	2010-10-14	Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE492545T1 (de)	2011-01-15	Verbindungen und zusammensetzungen als proteinkinase-hemmer
EP1841431A4 (en)	2009-12-09	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
CY2013014I2 (el)	2015-08-05	Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
DK1713806T3 (da)	2013-08-05	Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
CY2014012I2 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
ATE492544T1 (de)	2011-01-15	Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DK1943243T3 (da)	2011-03-07	Kinase-inhibitorer
NO20084739L (no)	2009-01-06	Substituerte 3-cyanopyridiner som protein kinase inhibitorer
DE602006019301D1 (de)	2011-02-10	Kinaseinhibitoren